Biliverdin reductase: a target for cancer therapy?

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Biliverdin reductase (BVR) is a key enzyme in bilirubin production, a potent antioxidant.
• BVR plays a regulatory role in crucial cell signaling pathways, including insulin/IGF-1/IRK/PI3K/MAPK.
• Elevated BVR expression is observed in various human tumors and immune cells, suggesting a role in cancer progression.

Purpose of the Study:

• To review recent findings on the pro-growth activities of Biliverdin reductase (BVR).
• To explore BVR's specific involvement in the MAPK signaling pathway.
• To present evidence for BVR-based peptides as a novel cancer therapeutic strategy.

Main Methods:

• Literature review of studies investigating BVR's role in cell signaling and cancer.
• Analysis of BVR's scaffold and intracellular transport functions for kinases.
• Evaluation of BVR-based peptide efficacy in inhibiting protein kinase activation.

Main Results:

• BVR acts as a scaffold and transporter for kinases regulating cell growth and proliferation.
• Activated BVR can translocate to the nucleus or plasma membrane, influencing diverse signaling pathways.
• BVR expression is upregulated in tumors and associated immune cells, correlating with cancer growth.

Conclusions:

• BVR's cytoprotective functions may inadvertently promote tumor growth.
• BVR-based peptides effectively inhibit key kinases (MEK, PKCδ, ERK) and downstream targets (Elk1, iNOS).
• BVR-targeting peptides represent a novel therapeutic approach to reduce cancer cell proliferation.